Education
About Us
Working with TipRanks
Follow Us
Lipocine (LPCN)
NASDAQ:LPCN
LPCN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.68 - $6.17
Previous CloseN/A
Volume16.76K
Average Volume (3M)26.46K
Market Cap
$15.77M
Enterprise Value-$1.02M
Total Cash (Recent Filing)$17.94M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)650.6
Beta1.02
Next Earnings
Nov 05, 2025EPS Estimate
-0.54Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.41
Shares Outstanding5,419,047
10 Day Avg. Volume19,065
30 Day Avg. Volume26,458
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap-0.06
Enterprise Value/Revenue-0.24
Enterprise Value/Gross Profit0.30
Enterprise Value/Ebitda0.19
Forecast
1Y Price Target
$7.38Price Target Upside154.48% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
Clinical TrialsPositive results from the Phase 3 trial in postpartum depression could support a global registration package for LPCN 1154.
Market NeedsPerinatal depression is under-diagnosed and under-treated, which may lead to adverse outcomes for the mother and the child, indicating a significant market need for effective treatments like LPCN 1154.
Regulatory ApprovalPotential regulatory approval and commercialization of TLANDO in Canada could help drive Lipocine’s topline revenue.
Bears Say
Clinical Trials RisksRisks include, but are not limited to: failure of LPCN 1154 in clinical trials and failure to obtain regulatory approval.
Market CompetitionRisks include failure to achieve commercial success due to reimbursement, penetration rate, and/or competition.
Lipocine News
LPCN FAQ
What was Lipocine’s price range in the past 12 months?
Lipocine lowest stock price was $2.68 and its highest was $6.17 in the past 12 months.
What is Lipocine’s market cap?
Lipocine’s market cap is $15.77M.
When is Lipocine’s upcoming earnings report date?
Lipocine’s upcoming earnings report date is Nov 05, 2025 which is in 62 days.
How were Lipocine’s earnings last quarter?
Lipocine released its earnings results on Aug 05, 2025. The company reported -$0.41 earnings per share for the quarter, missing the consensus estimate of -$0.4 by -$0.01.
Is Lipocine overvalued?
According to Wall Street analysts Lipocine’s price is currently Undervalued.
Does Lipocine pay dividends?
Lipocine does not currently pay dividends.
What is Lipocine’s EPS estimate?
Lipocine’s EPS estimate is -0.54.
How many shares outstanding does Lipocine have?
Lipocine has 5,419,047 shares outstanding.
What happened to Lipocine’s price movement after its last earnings report?
Lipocine reported an EPS of -$0.41 in its last earnings report, missing expectations of -$0.4. Following the earnings report the stock price went down -1.597%.
Which hedge fund is a major shareholder of Lipocine?
Currently, no hedge funds are holding shares in LPCN
Company Description
Lipocine
Lipocine Inc. (LPCN) is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutics based on its proprietary drug delivery technology. The company primarily operates in the healthcare sector, specializing in the treatment of metabolic and endocrine disorders, including testosterone deficiency and liver disease. Lipocine's core products include LPCN 1144, an oral testosterone replacement therapy, and LPCN 1107, a treatment for nonalcoholic steatohepatitis (NASH), which leverage its unique lipid-based delivery system to enhance bioavailability and patient compliance.
LPCN Stock 12 Month Forecast
Average Price Target
$7.38
▲(154.48% Upside)
Technical Analysis
Edesa Biotech
―
Unity Biotechnology
―
Equillium
―
Calidi Biotherapeutics
―
Cingulate Inc
―
Ownership Overview
15.69% Insiders
5.26% Mutual Funds
<0.01% Other Institutional Investors
75.23% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---